PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for ...
PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany wi ...
Another place to seek out potentially explosive stocks is in the biotech space. These innovators are working on the ...
Zacks Investment Research on MSN
Agios Pharmaceuticals incurs narrower-than-expected Q4 loss
Agios Pharmaceuticals AGIO reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.97. In the year-ago quarter, the company had ...
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...
Hong Kong - High Court Rules On Trade Secret Misuse And Employee Negligence In Biotech Rivalry. Legal News and Analysis - Hong Kong - Intellectual Property, Labour & Employment - Conventus Law ...
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...
After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...
Need a fast pass to Gen Alpha slang? No cap, this will help you keep up. So I called on a true expert: Arieh Smith, the linguistics-loving YouTuber whose viral video of a speech delivered almost ...
Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...
DEAR DR. ROACH: I am an 82-year old man who was in good health until I found out that I have an issue in my left kidney. My ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results